BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 1,028 Shares

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 1,028 shares of the firm's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $260.00, for a total value of $267,280.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Lai Wang also recently made the following trade(s):

• On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The stock was sold at an average price of $251.37, for a total value of $118,143.90.
• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The stock was sold at an average price of $266.40, for a total transaction of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The shares were sold at an average price of $252.39, for a total transaction of $353,850.78.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock traded down $3.75 during midday trading on Thursday, reaching $263.38. 60,311 shares of the company's stock traded hands, compared to its average volume of 441,310. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $141.31 and a 52 week high of $287.88. The firm has a 50 day moving average of $247.22. The stock has a market capitalization of $28.87 billion, a P/E ratio of -70.80 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. As a group, equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ONC. JMP Securities set a $348.00 target price on BeOne Medicines in a research report on Friday, February 28th. Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Royal Bank Of Canada decreased their target price on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Sanford C. Bernstein set a $259.00 price target on shares of BeOne Medicines in a research note on Thursday, March 13th. Finally, TD Securities reiterated a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a research report on Thursday, April 24th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, BeOne Medicines currently has a consensus rating of "Buy" and an average price target of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.